[NA Eun-kyung, Edaily Reporter] On the 16th, the “Hutox Launch Symposium” was held at the JW Marriott Hotel in Hangzhou, Zhejiang Province, China. Dr. Chris Gunwoo Kim, Chief Director of Cellinique Clinic, delivers his lecture during the event.
Huons Group is accelerating its entry into the Chinese market with its botulinum toxin product, “Hutox.”
On the 16th, the “Hutox Launch Symposium” was held at the JW Marriott Hotel in Hangzhou, Zhejiang Province, China. Dr. Chris Gunwoo Kim, Chief Director of Cellinique Clinic, delivers his lecture during the event.
Huons Group affiliates Humedix and Huons BioPharma announced on the 20th that the “Hutox Launch Symposium” was successfully held on the 16th at the JW Marriott Hotel in Hangzhou, Zhejiang Province, China.
The symposium was hosted by Huons BioPharma’s local Chinese partner, IMeik Technology (hereinafter “IMeik”). The event featured the official announcement of the launch of the botulinum toxin product “Hutox” in China, along with an academic exchange program.
Through this symposium, Humedix and Huons BioPharma aimed to expand their engagement with local Chinese medical professionals and industry stakeholders, while boosting global brand awareness of Hutox.
During the event, Dr. Chris Gunwoo Kim, Chief Director of Cellinique Clinic, participated as a guest speaker to deliver a lecture on Hutox. Dr. Kim shared global trends in the use of botulinum toxin, practical clinical applications, and operational know-how for administering the product.
Hutox is an aesthetic and therapeutic pharmaceutical product containing botulinum toxin as its active ingredient. It is primarily used to reduce glabellar lines and crow’s feet.
In 2022, IMeik secured exclusive import and distribution rights for Huons BioPharma’s botulinum toxin products in the Greater China region (including Macau and Hong Kong). Following this, IMeik obtained marketing authorization for Hutox from China’s National Medical Products Administration (NMPA) last January.
For this launch event, Humedix leveraged its extensive network of Korean medical professionals to facilitate the speaker’s invitation and streamline academic communications.
An official from Huons Group stated, “This Hutox Launch Symposium was a meaningful opportunity to introduce the global applications and academic value of Hutox to local Chinese medical professionals and industry experts. Moving forward, we will continue to drive diverse academic and marketing initiatives to strengthen the brand competitiveness of Hutox in the global market.”
SK Eco Plant and KCC Corporation(002380)achieved a successful public offering of corporate bonds, drawing a favorable response in the bookbuilding process despite significant uncertainty caused by a s…
As medical technology advances, the treatment of human diseases is evolving toward “personalized” and “precision medicine.” Consequently, demand for personalized treatment and precision medicine is no…
On July 23, the domestic stock market surged as expectations for artificial intelligence (AI) investments combined with strong momentum in healthcare and biotechnology stocks. The tech-heavy KOSDAQ ma…
